- Home
- MIRA vs MYNZ Comparison
MIRA vs MYNZ Comparison
Compare MIRA & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- MYNZ
- Stock Information
- Founded
- MIRA 2020
- MYNZ 2021
- Country
- MIRA United States
- MYNZ Germany
- Employees
- MIRA N/A
- MYNZ N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- MYNZ Health Care
- Exchange
- MIRA Nasdaq
- MYNZ Nasdaq
- Market Cap
- MIRA 19.5M
- MYNZ 5.5M
- IPO Year
- MIRA 2023
- MYNZ 2021
- Fundamental
- Price
- MIRA $1.82
- MYNZ $1.96
- Analyst Decision
- MIRA Strong Buy
- MYNZ Buy
- Analyst Count
- MIRA 2
- MYNZ 2
- Target Price
- MIRA $14.00
- MYNZ $14.00
- AVG Volume (30 Days)
- MIRA 3.4M
- MYNZ 215.4K
- Earning Date
- MIRA 08-12-2025
- MYNZ 07-29-2025
- Dividend Yield
- MIRA N/A
- MYNZ N/A
- EPS Growth
- MIRA N/A
- MYNZ N/A
- EPS
- MIRA N/A
- MYNZ N/A
- Revenue
- MIRA N/A
- MYNZ $893,991.00
- Revenue This Year
- MIRA N/A
- MYNZ $26.06
- Revenue Next Year
- MIRA N/A
- MYNZ $4.97
- P/E Ratio
- MIRA N/A
- MYNZ N/A
- Revenue Growth
- MIRA N/A
- MYNZ N/A
- 52 Week Low
- MIRA $0.62
- MYNZ $1.34
- 52 Week High
- MIRA $5.01
- MYNZ $19.00
- Technical
- Relative Strength Index (RSI)
- MIRA 76.83
- MYNZ 54.01
- Support Level
- MIRA $1.07
- MYNZ $1.78
- Resistance Level
- MIRA $2.09
- MYNZ $2.12
- Average True Range (ATR)
- MIRA 0.17
- MYNZ 0.17
- MACD
- MIRA 0.09
- MYNZ 0.07
- Stochastic Oscillator
- MIRA 86.27
- MYNZ 65.90
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.